Pasithea Therapeutics Correlations
| KTTAW Stock | USD 0.02 0.00 0.00% |
The current 90-days correlation between Pasithea Therapeutics and Caribou Biosciences is -0.05 (i.e., Good diversification). The correlation of Pasithea Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Pasithea Therapeutics Correlation With Market
Average diversification
The correlation between Pasithea Therapeutics Corp and DJI is 0.13 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pasithea Therapeutics Corp and DJI in the same portfolio, assuming nothing else is changed.
Moving against Pasithea Stock
| 0.66 | KB | KB Financial Group | PairCorr |
| 0.63 | SHG | Shinhan Financial Earnings Call This Week | PairCorr |
| 0.58 | WF | Woori Financial Group Earnings Call Tomorrow | PairCorr |
| 0.57 | AVAL | Grupo Aval | PairCorr |
| 0.56 | KMDA | Kamada | PairCorr |
| 0.5 | FNMFO | Federal National Mortgage Earnings Call This Week | PairCorr |
| 0.42 | PFE | Pfizer Inc | PairCorr |
| 0.42 | NKTR | Nektar Therapeutics | PairCorr |
| 0.41 | BAC-PL | Bank of America | PairCorr |
| 0.4 | RCUS | Arcus Biosciences | PairCorr |
| 0.34 | CGEN | Compugen | PairCorr |
| 0.7 | DIS | Walt Disney | PairCorr |
| 0.69 | CSCO | Cisco Systems | PairCorr |
| 0.67 | AXP | American Express | PairCorr |
| 0.66 | MSFT | Microsoft Aggressive Push | PairCorr |
| 0.63 | IBM | International Business Earnings Call Tomorrow | PairCorr |
| 0.63 | AA | Alcoa Corp | PairCorr |
| 0.48 | INTC | Intel Earnings Call This Week | PairCorr |
| 0.45 | HD | Home Depot | PairCorr |
| 0.45 | CVX | Chevron Corp | PairCorr |
| 0.31 | WFC-PL | Wells Fargo | PairCorr |
Related Correlations Analysis
| 0.95 | 0.8 | 0.48 | 0.87 | 0.97 | CRBU | ||
| 0.95 | 0.85 | 0.64 | 0.95 | 0.95 | CRSP | ||
| 0.8 | 0.85 | 0.38 | 0.81 | 0.81 | VERV | ||
| 0.48 | 0.64 | 0.38 | 0.72 | 0.54 | BEAM | ||
| 0.87 | 0.95 | 0.81 | 0.72 | 0.91 | PRME | ||
| 0.97 | 0.95 | 0.81 | 0.54 | 0.91 | SANA | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Pasithea Stock performing well and Pasithea Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pasithea Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CRBU | 5.35 | 1.82 | 0.24 | (1.25) | 4.72 | 12.02 | 23.18 | |||
| CRSP | 2.87 | 0.91 | 0.22 | (4.35) | 2.87 | 7.09 | 17.92 | |||
| VERV | 4.62 | 1.49 | 0.36 | 2.19 | 3.08 | 8.32 | 83.78 | |||
| BEAM | 2.72 | 0.22 | 0.02 | 2.46 | 4.27 | 5.84 | 23.19 | |||
| PRME | 6.64 | 2.12 | 0.27 | (1.37) | 5.84 | 15.00 | 41.91 | |||
| SANA | 4.71 | 1.70 | 0.39 | 125.91 | 3.19 | 12.50 | 31.62 |
Pasithea Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Pasithea Therapeutics Corporate Management
| Stanley Gloss | Chief Officer | Profile | |
| MD BA | Ex CoFounder | Profile | |
| Tiago Marques | CEO Director | Profile | |
| Daniel Schneiderman | Chief Officer | Profile | |
| Graeme Currie | Chief Officer | Profile |